These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 18203414)

  • 21. Glucagonoma with necrolytic migratory erythema exhibiting responsiveness to subcutaneous octreotide injections.
    Lo CH; Ho CL; Shih YL
    QJM; 2014 Feb; 107(2):157-8. PubMed ID: 23389434
    [No Abstract]   [Full Text] [Related]  

  • 22. Metabolic remission with octreotide in patients with insulinoma.
    von Eyben FE; Grodum E; Gjessing HJ; Hagen C; Nielsen H
    J Intern Med; 1994 Mar; 235(3):245-8. PubMed ID: 8120520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Insulinoma and octreotide].
    Stehouwer C
    Ned Tijdschr Geneeskd; 1992 Jun; 136(25):1221. PubMed ID: 1614574
    [No Abstract]   [Full Text] [Related]  

  • 24. Malignant insulinoma: is combined treatment with verapamil and the long-acting somatostatin analogue octreotide (SMS 201-995) more effective than single therapy with either drug?
    Stehouwer CD; Lems WF; Fischer HR; Hackeng WH
    Neth J Med; 1989 Aug; 35(1-2):86-94. PubMed ID: 2550827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No effect of the long-acting somatostatin analogue octreotide in patients with insulinoma.
    Timmer R; Koningsberger JC; Erkelens DW; Thijssen JH; Lips CJ; Koppeschaar HP
    Neth J Med; 1991 Jun; 38(5-6):199-203. PubMed ID: 1922592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Attempt in treating benign insulinoma by delayed somatostatin. 2 cases].
    Picq R; Vialettes B; de la Tour d'Auvergne M; Joliot AY; Vague P
    Presse Med; 1988 Nov; 17(39):2087. PubMed ID: 2849769
    [No Abstract]   [Full Text] [Related]  

  • 27. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
    Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
    Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors.
    Lau SC; Abdel-Rahman O; Cheung WY
    Med Oncol; 2018 Aug; 35(9):123. PubMed ID: 30078166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short- and long-term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism.
    Vezzosi D; Bennet A; Courbon F; Caron P
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):904-11. PubMed ID: 18031316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Malignant insulinoma: lack of response to the somatostatin analog SMS 201-955].
    Ligorria C; Montaña E; Virgili N
    Med Clin (Barc); 1989 Nov; 93(17):676. PubMed ID: 2559266
    [No Abstract]   [Full Text] [Related]  

  • 31. Sandostatin desensitization--a strategy useful for patients with carcinoid tumors, intolerant to sandostatin.
    Vinjamaram S; Iyer R
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):225-6. PubMed ID: 20922390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatostatin analogues in the management of benign insulinomas.
    Laron Z
    Isr J Med Sci; 1990 Jan; 26(1):1-2. PubMed ID: 2155883
    [No Abstract]   [Full Text] [Related]  

  • 33. Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2.
    Romeo S; Milione M; Gatti A; Fallarino M; Corleto V; Morano S; Baroni MG
    Horm Res; 2006; 65(3):120-5. PubMed ID: 16479142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic treatment of a benign insulinoma using the long-acting somatostatin analogue SMS 201-995.
    Glaser B; Rösler A; Halperin Y
    Isr J Med Sci; 1990 Jan; 26(1):16-9. PubMed ID: 2155884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.
    Arnold R; Trautmann ME; Creutzfeldt W; Benning R; Benning M; Neuhaus C; Jürgensen R; Stein K; Schäfer H; Bruns C; Dennler HJ
    Gut; 1996 Mar; 38(3):430-8. PubMed ID: 8675099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors.
    Oda Y; Tanaka Y; Naruse T; Sasanabe R; Tsubamoto M; Funahashi H
    Surg Today; 2002; 32(8):690-4. PubMed ID: 12181718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effective therapy of insulinoma by using long-acting somatostatin analogue. A case report and literature review.
    Jawiarczyk A; Bolanowski M; Syrycka J; Bednarek-Tupikowska G; Kałużny M; Kołodziejczyk A; Domosławski P
    Exp Clin Endocrinol Diabetes; 2012 Feb; 120(2):68-72. PubMed ID: 22187292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malignant insulinoma: effects of a somatostatin analog (compound 201-995) on serum glucose, growth, and gastro-entero-pancreatic hormones.
    Osei K; O'Dorisio TM
    Ann Intern Med; 1985 Aug; 103(2):223-5. PubMed ID: 2861769
    [No Abstract]   [Full Text] [Related]  

  • 39. The use of SMS 201-995 (somatostatin analogue) in insulinomas. Additional case report and literature review.
    Hearn PR; Ahmed M; Woodhouse NJ
    Horm Res; 1988; 29(5-6):211-3. PubMed ID: 2851522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen].
    Wenger FA; Zieren HU; Jacobi CA; Müller JM
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1348-50. PubMed ID: 9931878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.